AstraZeneca AB

Suède


 
Quantité totale PI 2 961
Quantité totale incluant filiales 2 961 (+ 0 pour les filiales)
Rang # Quantité totale PI 403
Note d'activité PI 3,7/5.0    1 155
Rang # Activité PI 633
Parent AstraZeneca PLC
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

455 123
215 188
1 464 127
389
 
Dernier brevet 2024 - Pharmaceutical composition
Premier brevet 1979 - Gastric acid secretion inhibitin...
Dernière marque 2024 - TOZZANVI
Première marque 1950 - ASTRA

Filiales

1 subsidiaries with IP (0 patents, 0 trademarks)

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 P/S Pharmaceutical preparations and substances.
P/S Pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders
P/S Pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders
Invention Pharmaceutical composition. The invention concerns pharmaceutical compositions containing a hydr...
Invention 2-(2,4,5-substituted-anilino)pyrimidine compounds. The present invention relates to certain 2-(2...
Invention Methods for treating chronic obstructive pulmonary disease in an enhanced patient population usin...
P/S Pharmaceutical preparations and substances for use in oncology.
P/S Pharmaceutical preparations and substances.
P/S Pharmaceutical preparations and substances for use in oncology.
P/S Pharmaceutical preparations and substances
Invention Halo-substituted piperidines as orexin receptor modulators. The present application relates to c...
P/S Pharmaceutical preparations for use in oncology; Pharmaceutical preparations and substances for t...
Invention 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx3cr1. There are disclosed certain 2,4,6-...
Invention Chemical compounds. The specification relates to compounds of Formula (I): The specification r...
Invention Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases. Th...
Invention Antibody molecules and conjugates. The present disclosure relates to antibody molecules that bin...
Invention Lilrb2 binding proteins and uses thereof. The present disclosure relates to binding proteins (e.g...
Invention Molecular switches. Provided herein are compositions and methods that permit the controlled inter...
Invention Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase ...
Invention Tissue regeneration. Populations of cells for use in the treatment of kidney disease and methods ...
Invention 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octane derivatives as smarca...
Invention Smarca2 degraders and uses thereof. The present disclosure provides compounds represented by Form...
Invention Armored t cells. This disclosure relates to compositions and methods for treating cancer using po...
Invention Pyrrolopyrimidine carboxamides. Pyrrolopyrimidine carboxamides and pharmaceutically acceptable sa...
Invention Methods, compositions, and combinations for the treatment of ovarian cancer. The disclosure relat...
Invention Pharmaceutical compositions. The present specification relates to pharmaceutical compositions com...
Invention Treatment of lupus. The disclosure relates to methods and compositions for the treatment of SLE. ...
Invention Methods and combinations for treating cervical cancer. The disclosure relates to methods, combina...
Invention Anti-ifnar1 dosing regime for subcutaneous injection. The disclosure relates to methods and comp...
Invention Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer. A method ...
Invention Methods of treatment of chronic kidney disease. The application relates to methods of treating ch...
Invention Pseudomonas antibodies with modified fc regions and methods of use thereof. Pseudomonas aeruginos...
Invention Compositions and methods for treating late stage lung cancer. Disclosed are methods for treating...
P/S Pharmaceutical preparations and substances for use in oncology
P/S Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and s...
Invention Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breas...
P/S Pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders.
Invention Egfr tkis for use in the treatment of non-small lung cancer. The specification relates to epider...
Invention Combinations of kras inhibitor and atr inhibitor for the treatment of cancer. The present provide...
Invention Treatment of non-small cell lung cancer. The disclosure generally relates to methods and composit...
Invention Conjugates comprising cleavable linkers. The specification relates to conjugates comprising a li...
Invention Conjugates comprising cleavable linkers. The specification relates to conjugates comprising a lin...
Invention 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibi...
Invention Irak4 protacs. This specification relates to compounds according to Formula (I), which are of PRO...
Invention Method of treatment with mpo inhibitors. The present disclosure relates to methods of identifying...
Invention Fluidic mixer unit device for nanoparticle production. A device 100 for producing nanoparticles i...
Invention Irak4 protacs. This specification relates to compounds according to Formula (I), which are of PR...
Invention Compounds and their use. The specification generally relates to compounds of Formula (I), and ph...
P/S Pharmaceutical preparations and substances for use in oncology.
Invention Dose. The disclosure relates to methods and compositions for the treatment of type I IFN mediate...
Invention Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation...
P/S Pharmaceutical preparations and substances for the treatment of immune-mediated inflammatory dise...
2023 Invention Polq inhibitors. The specification generally relates to compounds of Formula (I): The specific...
P/S Pharmaceutical preparations and substances for the treatment of amyloidosis.
Invention Use of inhibitors to increase efficiency of crispr/cas insertions. The present disclosure provid...
2022 Invention Peptide dendrons and methods of use thereof. The specification relates to peptide dendrons compr...
Invention Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators. There are disclosed certain...
Invention Methods of treating inflammatory diseases with a selective glucocorticoid receptor modulator. Th...
Invention Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer. There are di...
Invention Devices and a system for detection and analysis of inhaler use. Devices, methods and a system fo...
Invention Ca s9 effector proteins with enhanced stability. Provided are Cas9 effector proteins having enha...
2021 Invention Steroid sparing. The disclosure relates to methods and compositions for the treatment of Systemi...